Protagenic therapeutics reports fourth quarter and full year 2023 results

Transitioned from pre-clinical to clinical stage company in fy 2023 phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with treatment-resistant depression, ptsd or generalized anxiety disorder, progressing through phase 1 portion plans to enroll final two out of five cohorts into the single dose portion of the phase 1 trial within the next month new york, ny / accesswire / april 1, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. "in 2023, protagenic therapeutics achieved a significant milestone as we began enrolling patients for our neuropeptide drug candidate, pt00114," said dr. garo armen, executive chairman.
PTIX Ratings Summary
PTIX Quant Ranking